Overview
Ischemic nephropathy results from significant reduction in renal blood flow, leading to impaired glomerular filtration and potential progression to chronic kidney disease or end-stage renal failure 5.Diagnosis
Clinical Presentation: Reduced glomerular filtration rate (GFR) with evidence of renal artery stenosis or bilateral renal artery involvement 15.
Imaging: Renal duplex Doppler ultrasonography or angiography to identify stenotic lesions 34.
Laboratory Tests: Elevated serum creatinine, decreased estimated glomerular filtration rate (eGFR), and presence of tubular injury markers 26.
Pathophysiological Indicators: Increased oxidative stress, altered vasoactive pathways (e.g., reduced nitric oxide, increased endothelin), and inflammatory markers 5.Management
Revascularization Procedures: Renal angioplasty with stenting, often with distal protection devices to minimize acute renal function decline 34.
Medical Therapy:
- Minocycline: Reduced apoptosis and inflammation; dose and duration not specified in abstracts 2.
- Antioxidants/Anti-inflammatory Agents: Consideration based on pathophysiology, though specific agents not detailed in abstracts 5.
Blood Pressure Control: Essential to manage hypertension, though specific antihypertensive classes not highlighted 15.Special Populations
Elderly: Commonly affected; revascularization procedures show promise in preserving renal function 34.
Comorbidities: Patients with progressive azotemia may benefit from renal artery stenting, but surgical risks must be carefully weighed 4.Key Recommendations
Consider Renal Angioplasty with Stenting for Ischemic Nephropathy: Effective in preserving long-term renal function and blood pressure control in patients with significant atherosclerotic renal artery stenosis 34 (Evidence: Strong).
Use of Minocycline May Reduce Renal Injury: Postulated to decrease apoptosis and inflammation in ischemic renal injury models 2 (Evidence: Moderate).
Monitor and Manage Oxidative Stress and Inflammation: Targeting pathways like nitric oxide and endothelin may mitigate fibrogenic mechanisms 5 (Evidence: Expert opinion).References
1 Valls-Lacalle L, Barba I, Miró-Casas E, Alburquerque-Béjar JJ, Ruiz-Meana M, Fuertes-Agudo M et al.. Succinate dehydrogenase inhibition with malonate during reperfusion reduces infarct size by preventing mitochondrial permeability transition. Cardiovascular research 2016. link
2 Kelly KJ, Sutton TA, Weathered N, Ray N, Caldwell EJ, Plotkin Z et al.. Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury. American journal of physiology. Renal physiology 2004. link
3 Holden A, Hill A. Renal angioplasty and stenting with distal protection of the main renal artery in ischemic nephropathy: early experience. Journal of vascular surgery 2003. link00606-2)
4 Rocha-Singh KJ, Ahuja RK, Sung CH, Rutherford J. Long-term renal function preservation after renal artery stenting in patients with progressive ischemic nephropathy. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2002. link
5 Lerman L, Textor SC. Pathophysiology of ischemic nephropathy. The Urologic clinics of North America 2001. link80034-3)
6 Roche Z, Rutecki G, Cox J, Whittier FC. Reversible acute renal failure as an atypical presentation of ischemic nephropathy. American journal of kidney diseases : the official journal of the National Kidney Foundation 1993. link80428-8)
7 Dean RH, Tribble RW, Hansen KJ, O'Neil E, Craven TE, Redding JF. Evolution of renal insufficiency in ischemic nephropathy. Annals of surgery 1991. link